CalbaTech is creating a subsidiary to enable it to take its stem cell service, the Stem Cell Microbank™, to the U.K. The subsidiary will seek to be listed on the London Stock Exchange.
CalbaTech focuses on the collection and banking of adult stem cells and providing products and platforms to the biotech, pharma, and academic research markets. It expects that this subsidiary will be managed entirely within the U.K. without distracting from its U.S. focus.
The company will license to its subsidiary any and all intellectual property related to stem cells along with any new intellectual property that it develops. The reach will be limited to the U.K. with an option for the continent of Europe based on performance.